Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2.

Autor: Pastoors D; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Havermans M; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Mulet-Lazaro R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Brian D; Stem Cell Group, UCL Cancer Institute, University College London, London, UK., Noort W; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer biology and immunology, Amsterdam, Netherlands., Grasel J; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany.; Division of Experimental Hematology, German Cancer Research Center, DKFZ69120 Heidelberg, Germany., Hoogenboezem R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Smeenk L; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands., Demmers JAA; Proteomics Center, Erasmus MC, Rotterdam, Netherlands., Milsom MD; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg, Germany.; Division of Experimental Hematology, German Cancer Research Center, DKFZ69120 Heidelberg, Germany., Enver T; Stem Cell Group, UCL Cancer Institute, University College London, London, UK., Groen RWJ; Department of Hematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, Netherlands.; Cancer Center Amsterdam, Cancer biology and immunology, Amsterdam, Netherlands., Bindels E; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Delwel R; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.; Oncode Institute, Utrecht, Netherlands.

Publikováno v: Science advances [Sci Adv] 2024 May 17; Vol. 10 (20), pp. eadk9076. Date of Electronic Publication: 2024 May 15.

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Autor: de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Barwick BG; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Gupta VA; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Dupéré-Richer D; University of Florida Health Cancer Center, Gainesville, FL, USA., Yamano S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Ishiguro K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Meyers RM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Bryan JG; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dharia NV; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., Aguirre AJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Groen RWJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gray NS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Culhane AC; Department of Data Sciences, Dana-Farber Cancer Institute & Harvard School of Public Health, Boston, MA, USA.; Limerick Digital Cancer Research Center, Health Research Institute, School of Medicine, University of Limerick, Limerick, Ireland., McFarland JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Dempster JM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA., Vazquez F; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. vazquez@broadinstitute.org., Tsherniak A; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. aviad@broadinstitute.org., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA. constantine_mitsiades@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA, USA. constantine_mitsiades@dfci.harvard.edu.

Publikováno v: Nature cancer [Nat Cancer] 2023 May; Vol. 4 (5), pp. 754-773. Date of Electronic Publication: 2023 May 26.

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.

Autor: Katsarou A; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Sjöstrand M; Center for Cell Engineering, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Naik J; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Mansilla-Soto J; Center for Cell Engineering, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Kefala D; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Kladis G; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Nianias A; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Ruiter R; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Poels R; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Sarkar I; LUMICKS, Pilotenstraat 41, 1059 CH Amsterdam, Netherlands., Patankar YR; LUMICKS, Pilotenstraat 41, 1059 CH Amsterdam, Netherlands., Merino E; LUMICKS, Pilotenstraat 41, 1059 CH Amsterdam, Netherlands., Reijmers RM; LUMICKS, Pilotenstraat 41, 1059 CH Amsterdam, Netherlands., Frerichs KA; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Yuan H; Kuros Biosciences BV, 3723 MB Bilthoven, Netherlands., de Bruijn J; Kuros Biosciences BV, 3723 MB Bilthoven, Netherlands.; School of Engineering and Materials Science, Queen Mary University of London, London E1 4NS, UK., Stroopinsky D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., Avigan D; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA., van de Donk NWCJ; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Zweegman S; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Mutis T; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Sadelain M; Center for Cell Engineering, Immunology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Groen RWJ; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands., Themeli M; Department of Hematology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, Netherlands.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 Dec 08; Vol. 13 (623), pp. eabh1962. Date of Electronic Publication: 2021 Dec 08.

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant.

Autor: Holthof LC; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Stikvoort A; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van der Horst HJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Gelderloos AT; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Poels R; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Li F; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Groen RWJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Zweegman S; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., van de Donk NWCJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., O'Dwyer M; Department of Medicine, National University of Ireland, Galway, Ireland., Mutis T; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.

Publikováno v: HemaSphere [Hemasphere] 2021 Apr 21; Vol. 5 (5), pp. e561. Date of Electronic Publication: 2021 Apr 21 (Print Publication: 2021).

Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.

Autor: Shirasaki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Matthews GM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gandolfi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., de Matos Simoes R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Buckley DL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Raja Vora J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sievers QL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Brüggenthies JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Dashevsky O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Poarch H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tang H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Bariteau MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Sheffer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Hu Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Downey-Kopyscinski SL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hengeveld PJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Glassner BJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Dhimolea E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Ludwig Center at Harvard, Boston, MA, USA., Ott CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Zhang T; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Kwiatkowski NP; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Schlossman RL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA., Culhane AC; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health, Boston, MA, USA., Groen RWJ; Department of Hematology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands., Fischer ES; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Vazquez F; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Tsherniak A; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Levy J; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Licht JD; University of Florida Health Cancer Center, Gainesville, FL, USA., Keats JJ; Translational Genomics Research Institute, Phoenix, AZ, USA., Boise LH; Department of Hematology and Medical Oncology and the Winship Cancer Institute, Emory University, Atlanta, GA, USA., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Bradner JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Gray NS; Harvard Medical School, Boston, MA, USA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA., Mitsiades CS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. Electronic address: constantine_mitsiades@dfci.harvard.edu.

Publikováno v: Cell reports [Cell Rep] 2021 Jan 05; Vol. 34 (1), pp. 108532.